Arbutus Biopharma Corp (NASDAQ: ABUS) is a Healthcare company (Biotechnology) with a market capitalization of $621M. The Maz Rating grades it against the other companies in its sector.
Arbutus Biopharma Corp's current Maz Rating and its five factor grades are for members: log in to see them.
At $4.05, Arbutus Biopharma Corp trades at 3.6x trailing earnings, 3.4x sales and 9.4x book value, with an EV/EBITDA of 1.6. Over the last twelve months it generated about $182M of revenue and $174M of net income. It runs an operating margin of 79.9% and a net margin of 121.2%. It shows return on equity of 129.1%, return on invested capital of 147.8% and a free cash flow yield of 35.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 1.40. Over the past 52 weeks the share price ranged from $3.04 to $5.45, with a beta of 0.62.
Arbutus Biopharma Corp does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Arbutus Biopharma Corp (ABUS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 37.3% / 30% · Interest income / Revenue 792.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 37.3% / 33% · Receivables / Mkt Cap (36m) 0.09% / 49% · Interest income / Revenue 792.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 37.3% / 33.33% · Receivables / Mkt Cap (24m) 0.09% / 33.33% · Interest income / Revenue 792.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 1.05% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 62.6% / 33.33% · Receivables / Avg Assets (4Q) 18.6% / 33.33% · Interest income / Revenue 792.6% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 99.4% / 33.33% · (Cash+Recv) / Total Assets 99.6% / 33.33% · Interest income / Revenue 792.6% / 5% | Fail |
No. As of September 2026, Arbutus Biopharma Corp (ABUS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Arbutus Biopharma Corp is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 792.6% of each dividend: Arbutus Biopharma Corp's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.